Limba
|
Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266) is a humanized monoclonal antibody directed against the tumor necrosis factor-like weak inducer of apoptosis receptor (TWEAKR) with potential antineoplastic, immunomodulating and antiangiogenic activities. MW : 150 kD.
Price | 16.249,00 RON (preturile sunt fara TVA) |
---|---|
Description |
Enavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266) is a humanized monoclonal antibody directed against the tumor necrosis factor-like weak inducer of apoptosis receptor (TWEAKR) with potential antineoplastic, immunomodulating and antiangiogenic activities. MW : 150 kD. |